What's in Azienda USL Reggio Emilia - IRCCS's pipeline?

Azienda USL Reggio Emilia - IRCCS has 6 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Azienda USL Reggio Emilia - IRCCS's portfolio?

Top competitors by shared drug class: Montefiore Medical Center, Soroka University Medical Center, Carolina Eyecare Physicians, LLC, GlaxoSmithKline, Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/azienda-usl-reggio-emilia-irccs.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Azienda USL Reggio Emilia - IRCCS — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azienda USL Reggio Emilia - IRCCS pipeline: 5 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Indomethacin suppository	Indomethacin suppository	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2	Pain management, Rheumatology, Gastroenterology
Dexamethasone+Tobramycin eye drop	Dexamethasone+Tobramycin eye drop	marketed	Corticosteroid + aminoglycoside antibiotic combination	Glucocorticoid receptor (dexamethasone); bacterial 30S ribosome (tobramycin)	Ophthalmology
Dexamethasone 0.1% ophthalmic suspension	Dexamethasone 0.1% ophthalmic suspension	marketed	Corticosteroid	Glucocorticoid receptor	Ophthalmology
Bromfenac 0.09 % Ophthalmic Solution	Bromfenac 0.09 % Ophthalmic Solution	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)	Ophthalmology
Bromfenac eye drop	Bromfenac eye drop	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)	Ophthalmology

Therapeutic area mix

Ophthalmology · 4
Pain management, Rheumatology, Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Montefiore Medical Center · 2 shared drug classes
Soroka University Medical Center · 2 shared drug classes
Carolina Eyecare Physicians, LLC · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Pfizer · 2 shared drug classes
Sanofi · 2 shared drug classes
Bausch & Lomb Incorporated · 2 shared drug classes
Sun Yat-sen University · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Azienda USL Reggio Emilia - IRCCS:

Cite this brief

Drug Landscape (2026). Azienda USL Reggio Emilia - IRCCS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-usl-reggio-emilia-irccs. Accessed 2026-05-17.